Use of Patiromer to transition chronic kidney disease patients with hyperkalemia to a plant-rich diet.

Brief description of study

We are looking to enroll patients with high concentrations of potassium ('hyperkalemia') and chronic kidney disease. The purpose of this study is to see if a drug, patiromer, can keep blood potassium levels in the normal range in people with chronic kidney disease and mild hyperkalemia (high blood potassium levels) who are transitioned to a plant rich diet that includes high potassium foods. We will also be looking at the effects of a plant rich diet on digestive symptoms, mineral imbalances, inflammation, impaired glucose control, high blood pressure and abnormal blood lipids. Relypsa, Inc. called Veltassa® (or patiromer) was approved by the Food and Drug Administration (FDA) in 2015 for management of hyperkalemia in people with chronic kidney disease. Patriomer has been shown to help lower blood potassium concentrations by binding to potassium in the digestive tract, causing it to be excreted with the medication in feces (stool).


Clinical Study Identifier: s17-00051
ClinicalTrials.gov Identifier: NCT03183778
Principal Investigator: David S. Goldfarb.


Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.